Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar;47(2):161-173.
doi: 10.1055/s-0041-1722862. Epub 2021 Feb 26.

Gene Therapy for Inherited Bleeding Disorders

Valder R Arruda  1   2   3 , Jesse Weber  2 , Benjamin J Samelson-Jones  1   2   3
Affiliations
Review

Gene Therapy for Inherited Bleeding Disorders

Valder R Arruda et al. Semin Thromb Hemost. 2021 Mar.

Abstract

Decades of preclinical and clinical studies developing gene therapy for hemophilia are poised to bear fruit with current promising pivotal studies likely to lead to regulatory approval. However, this recent success should not obscure the multiple challenges that were overcome to reach this destination. Gene therapy for hemophilia A and B benefited from advancements in the general gene therapy field, such as the development of adeno-associated viral vectors, as well as disease-specific breakthroughs, like the identification of B-domain deleted factor VIII and hyperactive factor IX Padua. The gene therapy field has also benefited from hemophilia B clinical studies, which revealed for the first time critical safety concerns related to immune responses to the vector capsid not anticipated in preclinical models. Preclinical studies have also investigated gene transfer approaches for other rare inherited bleeding disorders, including factor VII deficiency, von Willebrand disease, and Glanzmann thrombasthenia. Here we review the successful gene therapy journey for hemophilia and pose some unanswered questions. We then discuss the current state of gene therapy for these other rare inherited bleeding disorders and how the lessons of hemophilia gene therapy may guide clinical development.

PubMed Disclaimer

Conflict of interest statement

B.J.S.-J. reports personal fees from Pfizer, Bayer, and Genentech; grants from Spark Therapeutics and Uniqure outside the submitted work. V.R.A. has patents related to FV, FVIII, and FIX variants. All the other authors report no conflict of interest.

Figures

Fig. 1
Fig. 1
(Color online) Theoretical pharmacokinetic limitations of replacement therapies compared with gene therapy. Multiple doses (top arrows) of replacement therapies are required to maximize the time within the therapeutic window (green), resulting in a saw-tooth shaped graph of activity versus time (blue solid line). To achieve a clinically feasible administration frequency, replacement therapy may result in peak levels in the supratherapeutic range and trough levels in the subtherapeutic range, which can be associated with thrombosis and bleeding, respectively. The time outside the therapeutic window will depend on the pharmacokinetics of the replacement therapy including the recovery and half-life. Replacement therapies with short half-lives, such as FVII and FVIIa, are especially at risk for this problem. The pharmacokinetics of transgene levels after gene therapy administration (purple dashed line) largely avoid this risk by providing the continuous stable expression levels.
Fig-2
Fig-2
impact of adaptive immune responses to AAV on gene transfer efficacy. Both neutralizing antibodies and cytotoxic T cells limit AAV-based gene transfer. In the absence of neutralizing antibodies and a cytotoxic T cell response, AAV liver-directed gene therapy results in transgene expression (top). The cytotoxic T cell response can limit transgene expression if not treated with immunosuppression (middle). Neutralizing antibodies to the AAV capsid can prevent efficient transduction for systemically administered AAV and prevent transgene expression (bottom). AAV, adeno-associated virus.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

  • Illustrated State-of-the-Art Capsules of the ISTH 2022 Congress.
    Ariëns RA, Hunt BJ, Agbani EO, Ahnström J, Ahrends R, Alikhan R, Assinger A, Bagoly Z, Balduini A, Barbon E, Barrett CD, Batty P, Carneiro JDA, Chan WS, de Maat M, de Wit K, Denis C, Ellis MH, Eslick R, Fu H, Hayward CPM, Ho-Tin-Noé B, Klok FA, Kumar R, Leiderman K, Litvinov RI, Mackman N, McQuilten Z, Neal MD, Parker WAE, Preston RJS, Rayes J, Rezaie AR, Roberts LN, Rocca B, Shapiro S, Siegal DM, Sousa LP, Suzuki-Inoue K, Zafar T, Zhou J. Ariëns RA, et al. Res Pract Thromb Haemost. 2022 Jul 6;6(5):e12747. doi: 10.1002/rth2.12747. eCollection 2022 Jul. Res Pract Thromb Haemost. 2022. PMID: 35814801 Free PMC article. Review.
  • The Arrival of Gene Therapy for Patients with Hemophilia A.
    Castaman G, Di Minno G, De Cristofaro R, Peyvandi F. Castaman G, et al. Int J Mol Sci. 2022 Sep 6;23(18):10228. doi: 10.3390/ijms231810228. Int J Mol Sci. 2022. PMID: 36142153 Free PMC article. Review.
  • The Clinical Genetics of Hemophilia B (Factor IX Deficiency).
    Miller CH. Miller CH. Appl Clin Genet. 2021 Nov 23;14:445-454. doi: 10.2147/TACG.S288256. eCollection 2021. Appl Clin Genet. 2021. PMID: 34848993 Free PMC article. Review.
  • Preoperative diagnosis and management of inherited bleeding disorders in female adolescents and adults.
    Wilson RD. Wilson RD. Can J Surg. 2023 May 2;66(3):E246-E263. doi: 10.1503/cjs.005922. Print 2023 May-Jun. Can J Surg. 2023. PMID: 37130707 Free PMC article. Review.
  • Gene Therapy in Hemophilia: Recent Advances.
    Rodríguez-Merchán EC, De Pablo-Moreno JA, Liras A. Rodríguez-Merchán EC, et al. Int J Mol Sci. 2021 Jul 17;22(14):7647. doi: 10.3390/ijms22147647. Int J Mol Sci. 2021. PMID: 34299267 Free PMC article. Review.

References

    1. Peyvandi F, Kunicki T, Lillicrap D. Genetic sequence analysis of inherited bleeding diseases. Blood 2013;122(20):3423–3431 - PMC - PubMed
    1. Mariani G, Bernardi F. Factor VII deficiency. Semin Thromb Hemost 2009;35(04):400–406 - PubMed
    1. Sharma R, Flood VH. Advances in the diagnosis and treatment of Von Willebrand disease. Blood 2017;130(22):2386–2391 - PMC - PubMed
    1. Curnow J, Pasalic L, Favaloro EJ. Treatment of von Willebrand disease. Semin Thromb Hemost 2016;42(02):133–146 - PubMed
    1. Nurden AT, Pillois X, Wilcox DA. Glanzmann thrombasthenia: state of the art and future directions. Semin Thromb Hemost 2013;39(06):642–655 - PMC - PubMed